Summary: Researchers developed a novel peptide, KS-133, to target cognitive dysfunction in schizophrenia. By using a brain-targeting peptide, KS-487, they successfully transported KS-133 across the blood-brain barrier. Their nanoparticle-based drug…
- Monday, November 4, 2024
